Although DT2216 is the only PROTAC molecule undergoing clinical trials for degrading BCL-xL, it is less effective in treating solid tumors and some specific forms of leukemia that are co-dependent on both BCL-xL and BCL-2 for survival, when administered alone and needs to be supplemented with ABT199 for better efficacy11. This evidence concerns the gene BCL2 and leukemia.